IMAB
NASDAQ
I-MAB - American Depositary Shares
Healthcare
· Biotechnology
$4.03
-0.31 (-7.1%)
4
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$366.7M
ROE
-18.5%
Margin
-439.8%
D/E
0.00
Beta
1.61
52W
$1–$7
Price Chart
Fundamentals Trend
| Metric | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -1.9% | -3.4% | -18.5% | -3.4% | -18.5% | -18.5% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | — | -439.8% | -439.8% | -439.8% |
| Gross Margin | — | — | — | 100.0% | 100.0% | 100.0% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 20.95 | 22.32 | 22.86 | 22.32 | 22.86 | 22.86 |
Key Ratios
ROA (TTM)
-17.5%
P/S (TTM)
7.75
P/B
0.3
EPS (TTM)
$-0.20
Rev Growth 3Y
-73.8%
52W High
$6.79
52W Low
$0.60
$0.60
52-Week Range
$6.79
How does IMAB compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
IMAB valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
7.8
▼
40%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
0.3
▼
86%
below
peers
(2.5)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
IMAB profitability vs Biotechnology peers
ROE
-18.5%
▲
72%
above
peers
(-67.3%)
vs Peers
vs Industry
Top tier
Net margin
-439.8%
▼
53%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
100.0%
▲
27%
above
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-17.5%
▲
63%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
IMAB financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
22.9
▲
415%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
1.6
▲
66%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
IMAB fundamentals radar
IMAB
Peer median
Industry
IMAB profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio